Dice Therapeutics

We are developing a portfolio of first-in-class selective inhibitors to treat intractable autoimmune diseases that cannot be prevented and for which there is no cure and only treatments with high rates of failure. Founded in 2016, we are funded by BiovelocITA, Sofinnova Partners, JDRF and a number of private investors. We develop first-in-class biologics for several underserved autoimmune conditions. By targeting the IGFBP3/TMEM219 axis and its dysregulation, we aim to provide safe and effective therapeutics for autoimmune diseases with high unmet medical need. Our proprietary discovery engine delivers libraries of monoclonal antibodies (mAbs) and fusion proteins that target the IGFBP3/TMEM219 pathway. Our current focus is the in-house development of two clinical candidates. Ent001, our lead program, is the only drug in development with the potential to preserve and restore the endogenous pancreatic beta cells compartment in T1D as well as the original intestine structure in IBD, in order to re-stablish organ function. Our discovery engine delivers libraries of monoclonal antibodies (mAbs) and fusion proteins that target the IGFBP3/TMEM219 pathway.

We are driven by science—and supported by a culture of innovation, openness and problem-solving. Our mission is to identify, develop and commercialize novel therapeutics that target diseases resulting from a loss of gastrointestinal barrier integrity. We are advancing a proprietary targeted prodrug platform to address the two most common forms of inflammatory bowel disease (IBD), ulcerative colitis and Crohn’s disease. Palisade Bio is a biopharmaceutical company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. IBD represents a multi-billion-dollar market opportunity in need of innovative approaches, with current therapies achieving a clinical remission rate of less than 20% on average. Palisade Bio’s lead program, PALI-2108 is a microbiota-activated PDE4 inhibitor prodrug being developed for the treatment of moderate-to-severe ulcerative colitis and is advancing toward the completion of IND-enabling studies and an IND filing. Our leadership is comprised of a team of experts in clinical development, commercialization, and pipeline development who are passionate about the advancement of science and medicine. The Palisade Bio team is dedicated to identifying and developing new therapies for a range of serious, widespread health conditions that impact millions of patients every year.

We are a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Our mission is to improve patient outcomes and save lives. To achieve our mission, we are capitalizing on groundbreaking scientific and medical discoveries at some of the world’s foremost research and academic institutions.

We are experienced biotech innovators with a vision to make chronic inflammatory disease treatable at its source. Our approach is built on the mounting body of scientific evidence supporting the NLRP3 inflammasome as the upstream catalyst and key driver of inflammation – a biological cascade that drives many chronic diseases of the body and brain.

We are a fast growing pharmaceutical company which develops and commercialises innovative first-in-class approaches for treatment of cancers, infections, autoimmune diseases and other life-threatening disorders. Our mission is to provide patients with more efficient and safer products in areas where their needs are not met. Our vision is that medicines work best when they are delivered to the right place at the right time. The main aim of the company is to provide patients and the market with more efficient and safe products in areas where these needs are unmet. Thus, the aim of the company is to design better and safer medicinal products for patients suffering from diseases such as cancer, inflammation, asthma or diabetes since the primary end-point is the wellbeing of the patient. In our strategy to develop new medicines, we are combining already known efficient approaches with our innovative first-in-class technologies to provide new therapeutic possibilities for treatment of life-threatening diseases. Science is the highest personification of the nation because that nation will remain the first which carries the furthest the works of thought and intelligence.”. We focus on the redevelopment of known drugs by changing the route of administration to develop new formulations designed to reduce side effects and improve efficacy.

We are a private clinical-stage biopharmaceutical company developing innovative and patent protected therapeutics for oncology and diseases of the immune system, with the goal of transforming patients’ lives. Dedicated to developing pharmaceuticals in oncology and immunomodulation. Our initial focus is the development of next generation therapeutics to improve outcomes with people with blood cancers.